# Brixton Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/brixton-biosciences

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.brixtonbio.com
- Total disclosed funding: $33M
- Latest round: Series B (May 14, 2024)
- Investors on record: 6

## About

Founded in 2019 by co-founder Sameer Sabir and based in Massachusetts, US, Brixton Biosciences, Inc. is a provider of a therapy designed to provide pain relief through a targeted injection. In May 2024, Brixton Biosciences, Inc. raised USD 33 million in Series B funding led by investor Schooner Capital, with participation from other investors such as SV Health Investors, Sparta Group, Excelestar Ventures, PV Capital, and Catalyst Health Ventures. The series B funding values Brixton Biosciences, Inc. at USD 45.08 million post-money.

The primary product of Brixton Biosciences is neural ice, an injectable solution designed to deliver targeted pain relief through a process called cryoneurolysis. This technique involves using a specialized ice slurry to induce temporary desensitization of nerves, which provides pain relief. The approach addresses acute and chronic pain conditions by leveraging selective cryoneurolysis to desensitize pain in specific areas.

The company will use the May 2024 funding to support the technological advancement of its offerings.

## Funding rounds

- Series B, May 14, 2024, $33M — SV Health Investors, Catalyst Health Ventures, Schooner Capital, Sparta Group, Excelestar Ventures, PV Capital

## Investors

- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series B
- Catalyst Health Ventures (https://capitalatlas.ai/funds/catalyst-health-ventures) — Series B
- Schooner Capital (https://capitalatlas.ai/funds/schooner-capital) — Series B
- Sparta Group — Series B
- Excelestar Ventures (https://capitalatlas.ai/funds/excelestar-ventures) — Series B
- PV Capital (https://capitalatlas.ai/funds/pv-capital) — Series B